Erdosteine

Bezeichnung:Erdosteine

CAS-Nr84611-23-4

Englisch Name:Erdosteine

CBNumberCB0230173

SummenformelC8H11NO4S2

Molgewicht249.31

MOL-Datei84611-23-4.mol

Erdosteine physikalisch-chemischer Eigenschaften

Schmelzpunkt	156-160°C
Siedepunkt	590.4±50.0 °C(Predicted)
Dichte	1.48±0.1 g/cm3(Predicted)
storage temp.	Sealed in dry,2-8°C
Löslichkeit	Acetonitrile (Slightly), DMSO (Slightly), Methanol (Slightly)
pka	3.71(at 25℃)
Aggregatzustand	Solid
Farbe	White to Off-White
maximale Wellenlänge (λmax)	236nm(H2O)(lit.)
Merck	14,3647
InChIKey	QGFORSXNKQLDNO-UHFFFAOYSA-N
CAS Datenbank	84611-23-4(CAS DataBase Reference)

Sicherheit

RTECS-Nr.	AJ1476200
HS Code	2934.99.9001
Toxizität	LD50 in mice and rats (g/kg): >10 orally; >3.5 i.v. (Gonella)

Gefahreninformationscode (GHS)

Erdosteine Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Erdosteine is a new expectorant introduced in France for the treatment of chronic bronchitis. Erdosteine possesses mucomodulator, mucolytic, mucokinetic and free radical scavenging properties. Its therapeutic efficacy has been demonstrated in patients affected by congestion and viscous mucus in higher and lower respiratory tracts as in acute and chronic bronchitis, sinusitis, otitis, tracheopharyngitis and coryza. Erdosteine acts through its active metabolites containing free sulfhydryl groups which are able to depolymerize the mucopolysaccharides of the excreatum by breaking the disulfide linkages (thereby lowing its viscosity). The prodrug approach provides unique characteristics to erdosteine by offering stable therapeutic efficacy and prevention of the gastric mucus from lythic phenomena. The agent was also reported to have local antiinflammatory and antielastase properties and enhances penetration of antibiotics into bronchial mucus.
Beschreibung
Erdosteine is a mucolytic agent and an antioxidant. It inhibits LPS-induced IκB kinase (IKK) activity, NF-κB-mediated transcription, and production of IL-6 and IL-1β in RAW 264.7 cells. Erdosteine (7.5 mg/kg) prevents depletion of renal catalase and glutathione peroxidase (GPX) and increases in renal malondialdehyde (MDA) and nitric oxide (NO) levels in a rat model of nephrotoxicity induced by cisplatin . It reduces spinal cord lipid peroxidation and destruction of spinal motor neurons in a rabbit model of spinal cord ischemia and reperfusion injury induced by thoracoabdominal aortic clamping. Erdosteine (150 mg/kg) reduces lung weight, MDA and protein carbonyl levels, and macrophage and neutrophil accumulation in a mouse model of acute lung injury induced by oleic acid (Item Nos. 90260 | 24659). Formulations containing erdosteine have been used in the treatment of chronic obstructive pulmonary disease (COPD).
Chemische Eigenschaften
Off-White Solid
Originator
Refarmed (Switzerland)
Verwenden
Erdosteine is a mucolytic. Erdosteine was developed for the treatment of chronic obstructive bronchitis.
Verwenden
A mucolytic, developed for the treatment of chronic obstructive bronchitis.
Definition
ChEBI: Erdosteine is a N-acyl-amino acid.
Trademarks
Edirel; Vectrine

Erdosteine Upstream-Materialien And Downstream Produkte

Erdosteine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

84611-23-4, Erdosteine Verwandte Suche:

Send Inquriy